Revolutions Medical (RMCP) 10-Q 19 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Revolutions Medical CORP	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	105,689,034
Amendment Flag	'false	'
Entity Central Index Key	'0001041009	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Balance_Sheets_Unaudited

Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets:	'	'
Cash and cash equivalents	$3,372	$54
Inventory	318,299	321,791
Prepaid expenses and other current assets	3,932	4,859
Total current assets	325,603	326,704
Property and equipment, net	291,805	356,656
Intangibles	120,621	106,687
Total assets	738,029	790,047
Current liabilities:	'	'
Accounts payable and accrued liabilities	1,534,129	1,122,371
Unearned revenue	106,690	'
Accounts payable and accrued liabilities, related parties	176,473	73,957
Payable for indemnification	1,372,466	1,347,806
Convertible notes, net of discounts of $216,394 and $187,039, respectively	312,150	184,289
Convertible notes, related parties, net of discounts of $0 and $42,534, respectively	75,000	32,466
Derivative liability, note conversion feature	409,986	364,802
Total liabilities	6,737,864	4,406,551
Commitments and contingencies	0	0
Series 2006 Preferred stock, $0.001 par value, 5,000,000 shares authorized; 1,000,000 shares issued and outstanding	1,000	1,000
Common stock, $0.001 par value; 250,000,000 shares authorized; 99,716,508 and 72,784,907 shares issued and outstanding, respectively	99,717	72,785
Additional paid-in-capital	35,957,222	34,319,432
Subscriptions receivable	-71,000	-71,000
Deficit accumulated during the development stage	-41,986,774	-37,938,721
Total stockholders' deficit	-5,999,835	-3,616,504
Total liabilities and stockholders' deficit	738,029	790,047
Yeso Med [Member]	'	'
Current liabilities:	'	'
Payable to Yeso-med	$2,750,970	$1,280,860

Balance_Sheets_Unaudited_Paren

Balance Sheets (Unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	99,716,508	72,784,907
Common stock, shares outstanding	99,716,508	72,784,907
Convertible Notes Payable [Member]	'	'
Convertible notes, discounts (in Dollars)	$216,394	$187,039
Convertible Notes Payable, Related Parities [Member]	'	'
Convertible notes, discounts (in Dollars)	$0	$42,534

Statements_of_Operations_Unaud

Statements of Operations (Unaudited) (2012 Period Restated) (USD $)	3 Months Ended		9 Months Ended		205 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenue	$2,363	$349	$5,454	$1,189	$6,643
Cost of revenue	1,338	219	2,640	9,200	11,840
Loss on firm purchase commitment	493,328	313,437	1,469,357	313,437	2,252,950
Cost of goods sold	494,666	313,656	1,471,997	322,637	2,264,790
Gross loss	-492,303	-313,307	-1,466,543	-321,448	-2,258,147
Operating expenses:	'	'	'	'	'
Research and development	'	9,900	'	99,588	2,935,949
Depreciation and amortization	24,789	23,925	72,727	53,888	277,838
General and administrative expenses	480,460	952,949	2,144,070	3,364,338	29,442,874
Impairment of assets	'	'	'	'	4,570,007
Gain on disposal of assets	'	'	'	'	-794
Total operating expenses	505,249	986,774	2,216,797	3,517,814	37,225,874
Operating loss	-997,552	-1,300,081	-3,683,340	-3,839,262	-39,484,021
Other income (expense):	'	'	'	'	'
Interest expense	-207,414	-489,696	-474,098	-1,529,699	-3,103,803
Investment income	'	'	'	'	170,753
Loss on extinguishment of debt	-4,082	'	-43,345	'	-183,057
Gain (loss) on change in fair value of derivative liabilities	283,382	-30,931	153,484	189,046	107,508
Other income (loss), net	'	-3,497	-753	-2,399	322,425
Total other income (expense)	71,886	-524,124	-364,712	-1,343,052	-2,686,174
Net loss	-925,666	-1,824,205	-4,048,052	-5,182,314	-42,170,195
Net loss attributable to the non-controlling interest	'	'	'	'	-183,422
Net loss attributable to Revolutions Medical Corp.	($925,666)	($1,824,205)	($4,048,052)	($5,182,314)	($41,986,773)
Net loss per common share - basic and diluted (in Dollars per share)	($0.01)	($0.03)	($0.05)	($0.09)	'
Weighted average number of common shares outstanding - basic and diluted (in Shares)	95,586,936	63,160,704	86,635,118	59,295,163	'

Statements_of_Cash_Flows_Unaud

Statements of Cash Flows (Unaudited) (2012 Period Restated) (USD $)	9 Months Ended		205 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net loss	($4,048,052)	($5,182,314)	($42,170,195)
Depreciation and amortization	72,727	53,888	277,838
Stock-based compensation	625,633	1,439,801	13,242,364
Stock options and warrants modification expense	188,628	'	238,628
Impairment of assets	'	'	4,570,007
Gain on disposal of assets	'	'	-794
Amortization of debt discounts	413,851	1,071,734	2,275,069
Interest expense incurred on issuance of convertible debt	2,838	146,445	399,312
Loss on extinguishment of debt	43,345	'	183,057
Gain (loss)on change in fair value of derivative liabilities	-153,484	-189,046	-107,508
Changes in operating assets and liabilities:	'	'	'
Inventory	3,492	-320,837	-318,299
Prepaid expenses and other current assets	927	-75,085	-3,932
Accounts payable and accrued liabilities	2,132,887	1,455,355	5,029,240
Accounts payable and accrued liabilities - related parties	90,016	-87,944	163,973
Unearned revenue	106,690	'	106,690
Payable for indemnification	24,660	41,108	1,830,056
Net cash used in operating activities	-495,842	-1,646,895	-14,284,494
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	'	'	-992,907
Proceeds from sale of fixed assets	'	'	794
Payments for license and patents	-21,810	-30,321	-183,348
Investment in Ives Health Company and The Health Club	'	'	-261,997
Net cash used in investing activities	-21,810	-30,321	-1,437,458
Cash flows from financing activities:	'	'	'
Capital contribution	'	'	802,154
Proceeds from issuance of common stock through cash exercise of stock options and warrants	100,000	305,444	3,512,412
Proceeds from issuance of notes for cash	472,500	1,368,001	3,448,501
Proceeds from loans from shareholders	'	'	15,707
Repayment of loans from shareholders	'	'	-8,005
Repayment of notes	-51,530	'	-208,855
Proceeds for issuance of common stock for cash	'	'	8,163,410
Net cash provided by financing activities	520,970	1,673,445	15,725,324
Net change in cash	3,318	-3,771	3,372
Cash at beginning of period	54	4,844	'
Cash at end of period	3,372	1,073	3,372
Non-cash financing and investing activities:	'	'	'
Common stock issued for conversion of debt	550,621	1,674,859	5,238,036
Shares issued for indemnification agreement	'	140,560	457,590
Debt discount on convertible notes	253,053	'	2,658,475
Beneficial conversion feature	130,117	436,184	488,879
Common stock issued for investment	'	'	289,009
Preferred stock forfeited	'	'	500
Ives Merger [Member]	'	'	'
Non-cash financing and investing activities:	'	'	'
Common stock issued in connection with Merger	'	'	300
Clear Image Shareholders under Short Form Merger [Member]	'	'	'
Non-cash financing and investing activities:	'	'	'
Common stock issued for acquisition of Clear Image	'	'	$3,093,948

Note_1_Basis_of_Presentation_D

Note 1 - Basis of Presentation, Description of Business, Summary of Significant Accounting Policies, Critical Accounting Estimates and Reclassification	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	'
	Note 1 – Basis of Presentation, Description of Business, Summary of Significant Accounting Policies, Critical Accounting Estimates and Reclassification
	Basis of Presentation
	The accompanying unaudited financial statements include the accounts of Revolutions Medical Corporation, a Nevada corporation. Unless the context otherwise requires, references to the “Company”, “RevMed”, “our”, “we”, and “us” mean Revolutions Medical Corporation.
	The Company follows accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB establishes accounting principles generally accepted in the United States (“GAAP”). Rules and interpretive releases of the U.S. Securities and Exchange Commission (“SEC”) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants, which the Company is required to follow. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification (“ASC”), which serves as a single source of authoritative non-SEC accounting and reporting standards to be applied by nongovernmental entities.
	The Company’s financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included.  The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Management has evaluated events and transactions that occurred after the balance sheet date and through the date these financial statements were issued and considered the effect of such events in the preparation of these financial statements.
	The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The financial statements contained herein should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
	Description of Business
	RevMed endeavors to design, develop and commercialize auto retractable vacuum safety syringes.  Our present product development effort is focused on the RevVac™ Auto Retractable Vacuum Safety Syringe (“RevVac™ Safety Syringe”), which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases.  The Company also has developed a suite of proprietary Magnetic Resonance Imaging (“MRI”) software tools consisting of RevColor™, Rev3D™, and RevDisplay™.  These tools are designed to enhance general diagnostic confidence through education and research use and in the future the Company believe will have specific commercial applications. The Company’s administrative facilities are located in Charleston, South Carolina and its primary manufacturing facility is located in Wuxi, China.
	Since its inception in 1996, the Company has been considered a development stage enterprise for financial reporting purposes as significant efforts have been devoted to raising capital for research and development of various safety syringes and its proprietary MRI software tools.
	Summary of Significant Accounting Policies, Critical Accounting Estimates and Reclassification
	Significant Accounting Policies
	The Company has established and followed a number of accounting policies in the preparation of these financial statements in conformity with GAAP.  Significant among these policies are policies related to cash and cash equivalents, inventories, property and equipment, intangibles, impairment of long-lived assets, research and development, convertible debt with beneficial conversion features, derivative instruments, fair value of financial instruments, revenue recognition and stock-based compensation.  These accounting policies are more fully described in the notes to the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2012.
	Critical Accounting Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.
	Reclassification
	Certain prior period amounts have been reclassified to conform to current period presentation.
	New and Pending Accounting Standards
	The Company does not anticipate that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company. In addition, the Company is evaluating other accounting standards and exposure drafts, such as exposure drafts related to revenue recognition, leases and fair value measurements, that have been issued or proposed by the FASB or other standard setting bodies that do not require adoption until a future date to determine whether adoption will have a material impact on the Company’s financial statements.

Note_2_Going_Concern

Note 2 - Going Concern	9 Months Ended
	Sep. 30, 2013
Going Concern Note [Abstract]	'
Going Concern Note	'
	Note 2 – Going Concern
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has not established significant sources of revenue to fund the development of its business and pay operating expenses, resulting in a cumulative net loss of $42 million for the period from inception (August 16, 1996) to September 30, 2013. The ability of the Company to continue as a going concern during the next year depends on successful sales of its RevVac™ Safety Syringe and completion of the Company’s capital raising efforts to fund the development of its 1ml, including insulin, 5ml and 10ml auto-retractable vacuum safety syringes. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note_3_Property_And_Equipment

Note 3 - Property And Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 3 – Property and Equipment
	Property and equipment consisted of the following:
		September 30,			December 31,
		2013			2012
	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(154,577	)		(89,726	)
		$	291,805		$	356,656
	For the nine months ended September 30, 2013 and 2012, the Company recognized depreciation and amortization expense related to property and equipment of $64,851 and $47,391, respectively.

Note_4_Intangibles

Note 4 - Intangibles	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	Note 4 – Intangibles
	Intangibles consisted of the following:
		September 30,			December 31,
		2013			2012
	Patent	$	168,348		$	146,538
	Less accumulated amortization		(47,727	)		(39,851	)
		$	120,621		$	106,687
	For the nine months ended September 30, 2013 and 2012, the Company recognized amortization expense of $7,876 and$6,497, respectively.

Note_5_Accounts_Payable_And_Ac

Note 5 - Accounts Payable And Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Note 5 - Accounts Payable And Accrued Liabilities [Line Items]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 5 – Accounts Payable and Accrued Liabilities
	Accounts payable and accrued liabilities consisted of the following:
		September 30,		December 31,
		2013		2012
	Accounts payable	$	491,959	$	432,436
	Accrued payroll liabilities and related penalties		598,815		411,670
	Accrued salary		295,273		143,167
	Accrued interest		147,543		134,559
	Other accruals		539		539
		$	1,534,129	$	1,122,371
	As of September 30, 2013 and December 31, 2012, the Company accrued $598,815 and $411,670, respectively, pursuant to state and federal payroll tax liabilities and related penalties.  Although the Company plans to settle these amounts, there is no assurance that its efforts to settle will be successful.  Tax liens in the aggregate amount of $6,457 were filed against the Company by the South Carolina Department of Revenue due to these delinquent payments and failure to file the required tax forms.   Action by federal taxing authorities has not been initiated or threatened at this point.  There is no assurance, however, that such action will not be initiated in the future. In October 2013, the Company obtained representation and is negotiating with the taxing authorities to resolve these liabilities.
Yeso Med [Member]	'
Note 5 - Accounts Payable And Accrued Liabilities [Line Items]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 6 – Payable to Yeso-med
	On December 1, 2011, the Company entered into a 5-year agreement with Wuxi Yushou Medical Appliance Co., Ltd (“Yeso-med”). Pursuant to the agreement, commencing from the date that Yeso-med demonstrates to the Company’s satisfaction that it has the capacity to commence regular production of the syringes in the 3ml size in the minimum amount of at least 2,500,000 units per month, the Company will place orders of at least 2,500,000 units per month for the term of this agreement. If the Company does not place with Yeso-med the minimum order for a single month, Yeso-med shall have the right to receive payments from the Company equal to 50% of the supply price of each unit below the minimum order amount required for that month.  The Company has the right to have the amount paid under this requirement to serve as payment against future orders provided the quantity ordered exceeds the minimum quantity for that month. In July 2012, Yeso-med met the capacity requirement. However, the Company has not yet placed an order as of September 30, 2013.  As of September 30, 2013 and December 31, 2012, a payable was recorded to Yeso-med related to this minimum purchase requirement of $2,252,950 and $783,593, respectively. For the nine months ended September 30, 2013 and 2012, $1.5 million and $313,437 was recorded as a loss on firm purchase commitments, respectively.
	The payable to Yeso-med also included amounts due for product purchased of $208,501 and $208,258 as of September 30, 2013 and December 31, 2012, respectively, and amounts due for equipment purchased of $289,519 and $289,009 as of September 30, 2013 and December 31, 2012, respectively.

Note_7_Payable_for_Indemnifica

Note 7 - Payable for Indemnification (Payable for Indemnification [Member])	9 Months Ended
	Sep. 30, 2013
Payable for Indemnification [Member]	'
Note 7 - Payable for Indemnification [Line Items]	'
Short-term Debt [Text Block]	'
	Note 7 – Payable for Indemnification
	On February 5, 2009, the Company entered into an Indemnification Settlement Agreement with Gifford M. Mabie, founder and former Chief Executive Officer of the Company. Pursuant to the agreement, the Company agreed to indemnify Mr. Mabie for the payment of penalties, prejudgment interest and post-judgment interest to the SEC that is part of the Final Judgment, dated March 11, 2005, in SEC v. Maxxon, Inc., Gifford M. Mabie, Jr., Thomas R. Coughlin, Jr. 02-CV-975-H(J) which resulted from actions taken in good faith by Messrs. Mabie and Coughlin in the performance of duties as an officer and directors of the Company.  The payment amount stated in the Final Judgment was $1,088,067.
	The agreement specifies that the Company is to periodically issue shares of its common stock to a special account for Mr. Mabie so that shares can be sold each day the market is open until the liability is satisfied.  The special account was initially funded by common stock owned by Mr. Mabie. The total number of shares sold from the special account is limited to 5% of the total trading volume each day. A percentage equal to Mr. Mabie’s federal and state tax liabilities up to a maximum of 40% will be retained by the brokerage firm administering the special account and remitted to the Internal Revenue Service and to the Oklahoma Tax Commission or the tax commission having jurisdiction in the state in which Mr. Mabie resides. In the event that Mr. Mabie is entitled to a tax refund, the refund will be remitted to the SEC.
	On December 14, 2010, the Company issued 400,000 shares of the Company’s common stock, initially valued at $184,000, to the special account. An additional 400,000 shares were issued to the special account on March 15, 2012 with a value of $140,560 determined based upon the 10-day average share price prior to the date of issuance.  At each reporting date, the Company revalues the shares held in the special account and adjusts the outstanding balance. Net increases and decreases in the value of the Company’s common shares held in the special account are recorded in the current period statement of operations. As of September 30, 2013 and December 31, 2012, the remaining principal balance, including the estimated taxes, to be paid was $1.4 million and $1.3 million, respectively, based upon the Company’s valuation of the stock. For the nine months ended September 30, 2013 and 2012, the net loss related to shares of the Company’s common stock held in the special account was $24,659 and $31,974, respectively. As of September 30, 2013, there were 301,463 shares of the Company’s common stock held in the special account.

Note_8_Convertible_Notes

Note 8 - Convertible Notes	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 8 – Convertible Notes
	Convertible notes consisted of the following:
		September 30,			December 31,
		2013			2012
	Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014	$	191,663		$	191,663
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on March 21, 2013, fully converted in 2013		-			7,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 10, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on August 27, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on December 6, 2013		27,500			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 19, 2014		35,000			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on December 19, 2013		23,411			-
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due on January 3, 2013		-			62,165
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due monthly until April 26, 2014		215,970			-
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on September 3, 2014		35,000			-
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on January 26, 2014		75,000			100,000
			603,544			446,328
	Less: debt discount		(216,394	)		(229,573	)
		$	387,150		$	216,755
	JMJ Financial
	On February 22, 2011, the Company issued a convertible promissory note in the amount of $1,050,000 to JMJ Financial, Inc. (“JMJ”). The note bears interest in the form of a one-time interest charge of 8%, payable with the note’s principal amount on the maturity date, February 22, 2014. The note is convertible to the Company’s common stock at a price equal to 70% of the average of the three lowest closing market prices of the Company’s common stock for the 20 trading days prior to the conversion date. In connection with the note, the Company entered into a registration rights agreement with JMJ to provide JMJ registration rights for common shares underlying this note. The note will only be funded when the conversion price calculated on each payment date is equal to or greater than $0.015 per share and there are sufficient shares remaining in the registration statement. During 2012, JMJ converted $15,498 under this agreement into 180,000 shares of the Company’s common stock. The principal amount owed to JMJ at September 30, 2013 and December 31, 2012 was $191,663 under the convertible promissory note. The Company analyzed the JMJ note for derivative accounting consideration and determined that the note qualifies for accounting treatment as a financial derivative and recorded an initial discount of $450,000 on the issuance date. For the nine months ended September 30, 2013 and 2012, the Company recorded $75,970 and $60,000 of interest expense related to the amortization of the debt discount. At September 30, 2013 and December 31, 2012, there was $30,721 and $106,691, respectively, of unamortized debt discount related to the JMJ notes.
	The Company is currently in litigation with JMJ. See Note 11.
	Asher Enterprises
	On February 28, 2013 and August 15, 2013, the Company issued convertible promissory notes to Asher Enterprises for proceeds of $42,500 and $35,000 in cash, respectively, (the “2013 Asher Notes”). The notes are convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest three trading prices for the Company’s common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date and (2) a fixed conversion price of $0.00009 per share. The Company analyzed the conversion feature of the 2013 Asher Notes for derivative accounting consideration and determined that the conversion features for the 2013 Asher Notes do not qualify for accounting treatment as a financial derivative. The 2013 Asher Notes have an aggregate beneficial conversion feature discount of $77,500, of which $41,661 was amortized as interest expense for the nine months ended September 30, 2013. For the nine months ended September 30, 2013, the Company also recorded interest expense of $66,930 related to the amortization of debt discount on notes issued in 2012 to Asher Enterprises. At September 30, 2013, there was $35,839 of unamortized discount related to the outstanding 2013 Asher Notes.
	During the nine months ended September 30, 2013, Asher Enterprises converted principal of $97,600 with accrued interest related to notes issued in 2012 into 2,726,118 shares of the Company’s common stock. In addition, on September 12, 2013, Asher Enterprises converted principal of $15,000 related to the note issued in 2013 into 1,339,286 shares of the Company’s common stock.
	Carebourn Capital
	On March 19, 2013, the Company issued a convertible promissory note to Carebourn Capital for proceeds of $60,000 in cash. (“2013 Carebourn Note”). The note is convertible to the Company’s common stock at a conversion price equal to the greater of (1) 55% multiplied by the average of the lowest three trading prices for the Company’s common stock during the 10 trading day period ending on the latest completed trading day prior to the conversion date (2) a fixed conversion price of $0.00009 per share. The Company analyzed the conversion feature of the 2013 Carebourn Note for derivative accounting consideration and determined that the conversion feature for the 2013 Carebourn Notes does not qualify for accounting treatment as a financial derivative. The 2013 Carebourn Note has a beneficial conversion feature discount of $49,091, of which $43,519 was amortized as interest expense for the nine months ended September 30, 2013. At September 30, 2013, there was $5,572 of unamortized discount related to the 2013 Carebourn Note. On September 20, 2013, Carebourn Capital converted principal of $36,590 related to this note into 2,350,000 shares of the Company’s common stock.
	TCA Global Credit Master Fund, LP
	2012 TCA Securities Purchase Agreement
	On January 3, 2012, the Company entered into a securities purchase agreement with TCA Global Credit Master Fund, LP (“TCA”), pursuant to which, TCA would purchase up to $2,000,000 of the Company’s common stock. The Company agreed to pay a $100,000 facility fee by issuing to TCA a number of the Company’s common shares (“facility shares”). To determine the number of shares issuable to TCA for the facility fee, the Company’s common stock was valued at a volume weighted average price at January 2, 2012. The facility shares should be adjusted nine months after January 2, 2012 by the volume weighted average prices of the Company’s common stock five trading days prior to the revaluation date. The Company issued 559,268 common shares in 2012 to TCA which satisfied $51,924 of the facility fee upon revaluation. On August 13, 2012, the Company and TCA agreed to terminate the committed equity financing agreement based on the Company’s failure to achieve bulletin board listing as required under the agreement.
	In connection with the securities purchase agreement with TCA, the Company issued a convertible promissory note to TCA for a principal amount of $225,000 (“TCA Note”).  The note bears interest at a rate of 12% per annum and provides for the payment of all principal and interest 12 months from the date of the note’s issuance.  The conversion price was determined by multiplying 95% by the average of the two lowest daily volume weighted average prices of the Company’s common stock on the OTC Markets during the five business days immediately preceding the date of conversion.  The Company analyzed the TCA Note for derivative accounting consideration and determined that the TCA Note qualifies for accounting treatment as a financial derivative. The conversion feature of the TCA Note was valued at $174,448 on the issuance date and recorded as debt discount which was fully amortized in 2012.
	TCA converted principal of $27,840 into 300,000 shares of the Company’s common stock on January 3, 2013. On May 9, 2013, 1,750,000 shares, valued at $140,000, were issued to TCA to settle all outstanding liabilities related to the January 2, 2012 security purchase agreement which totaled $106,987. The Company recorded a $33,013 loss on extinguishment of debt related to the settlement. There is a leak out provision provided in this settlement. TCA shall return all remaining shares back to the Company once proceeds of the sale of shares from the 1,750,000 shares issued reached $80,000 and the Company will issue additional shares to TCA if all shares issued on May 9, 2013 are sold and total net proceeds do not reach $80,000.
	2013 TCA Securities Purchase Agreement
	On April 26, 2013, the Company entered into a securities purchase agreement with TCA, pursuant to which, TCA shall purchase from the Company up to $2,000,000 of senior secured convertible redeemable debentures (the “Debentures”). The Debentures will be purchased in a series of closings and pursuant to the first such closing, TCA purchased that certain senior convertible redeemable debenture in the amount of $250,000.
	The Debentures were issued at 7% discount and the discount of $17,500 is amortized over one year, the term of the Debentures, using straight-line method. The note bears interest at a rate of 12% per annum and the Company shall make monthly payments of principal and interest commencing on May 26, 2013 with the first two payments only including interest. If all or any portion of the payments of principal and interest is late, the Company should pay TCA a late charge equal to 5% of such unpaid payment. During the nine months ended September 30, 2013, the Company made principal payments of $51,530 and interest payments of $9,761 to TCA.
	The Debentures are convertible at a price determined by multiplying 85% of the average daily volume weighted average price of the Company’s common stock during the five business days immediately preceding the date of conversion. The Company analyzed the Debentures for derivative accounting consideration and determined that the Debentures qualify for accounting treatment as a financial derivative. The conversion feature of the Debentures was valued at $218,053 on the issuance date and recorded as debt discount. As of September 30, 2013, there was $111,893 of unamortized debt discount related to the Debentures.
	The Company also issued to TCA 9,375,000 shares, which were pledged as security for the securities purchase agreement and was held with an escrow agent until such time as the full payment and performance of all of the obligations of the Company have been satisfied in accordance with the terms of said agreement. The Company also granted TCA the right to vote and receive dividends during the period the 9,375,000 shares were held by TCA. The Company recorded shares issued at par value of $9,375 with an offset to additional paid-in capital.
	On May 9, 2013 the Company issued 2,000,000 restricted shares to pay for the $100,000 facility fee pursuant to the 2013 TCA securities purchase agreement entered into April 26, 2013 with TCA. TCA will return all remaining shares to the Company if total net proceeds of $100,000 are reached and the Company will issue additional shares if a total of 2,000,000 shares are sold and net proceeds do not total $100,000.
	2012 Individual Convertible Notes Payable
	During 2012, the Company issued 22 convertible notes payable to individuals for proceeds of $956,501 in cash (“Individual Convertible Notes”). The Individual Convertible Notes mature one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity.
	The principal amount of the Individual Convertible Notes and accrued interest are convertible into the Company’s common stock at a conversion price equal to 75% of the average of the daily volume weighted average prices of the Company's Common Stock during the five trading days immediately prior to the conversion date, provided that in no event, shall the note holders convert any portion of the Individual Convertible Notes when the sum of (1) the number of shares of common stock beneficially owned by the holder and its affiliates and (2) the number of shares of common stock issuable upon conversion would result in beneficial ownership by the holder and its affiliates of more than 4.99% of the Company’s outstanding common shares. During the nine months ended September 30, 2013, $25,000 of the Individual Convertible Notes with accrued interest was converted into 353,727 shares of the Company’s common stock. As of September 30, 2013 and December 31, 2012, Individual Convertible Notes included principal of $75,000 payable to Vincent Olmo, the Company’s COO, with a debt discount of $0 and $42,534, respectively. This note was extended on November 5, 2013 and is due January 26, 2014.
	In connection with the issuance of the Individual Convertible Notes, warrants to purchase 3,826,005 shares of the Company’s common stock at $0.25 per share (“$0.25 Warrant”) and warrants to purchase 1,913,003 shares of the Company’s common stock at $0.50 per share (“$0.50 Warrant”) were issued to investors. The warrants have a term of less than one year and expire during the period beginning December 31, 2012 and ending June 30, 2013.
	Of the $956,501 proceeds received from the Individual Convertible Notes, $347,097 was allocated to the warrants based on a grant date fair value of $589,416 calculated using the Black-Scholes-Merton option pricing model (“Black-Scholes Model”) with the following assumptions: (1) 3.9% risk-free discount rate, (2) expected volatility of 155.60 ~218.64%, (3) $0 expected dividends, and (4) an expected term of 0.3~1 years based on the term of warrant.
	On March 1, 2013, the Company extended the expiration date of the $0.25 warrants to June 30, 2013 and the $0.50 warrants to September 30, 2013. Warrants to purchase 2,859,008 shares of the Company’s common stock that originally expired on December 31, 2012 were reissued to the note holders. The Company recorded a $148,127 modification expense related to the extension.
	On August 28, 2013, the Company further extended the expiration date of the $0.25 warrants to June 30, 2014 and the $0.50 warrants to September 30, 2014. The Company recorded a $40,501 modification expense related to the extension.
	The Company analyzed the Individual Convertible Notes for derivative accounting consideration and determined that the conversion feature of the Individual Convertible Notes qualify for accounting treatment as a financial derivative. The conversion feature of Individual Convertible Notes was valued at $777,766 on the issuance date. As a result, some of the Individual Convertible Notes were fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the Individual Convertible Notes of $182,733 was expensed immediately as additional interest expense. For the nine months ended September 30, 2013, the Company recognized $55,952 of interest expense related to the amortization of the debt discount. At September 30, 2013 and December 31, 2012, there was $0 and $55,952 of unamortized discount related to the Individual Convertible Notes, respectively.
	2013 Individual Convertible Notes Payable
	On April 25, 2013, the Company issued a $50,000 convertible note to an individual together with warrants to purchase 200,000 shares of the Company’s common stock at $0.25 per share and 100,000 shares of the Company’s common stock at $0.50 per share. These warrants were valued at $3,526, calculated using the Black-Scholes Model. The individual investor converted the $50,000 convertible promissory note into 1,000,000 shares of the Company’s common stock on the same date the note was issued.
	On September 3, 2013, the Company issued a $35,000 convertible note to an individual. The note matures one year from the date of issuance. Interest accrues at the rate of 8% per year on the outstanding principal amount to be paid at maturity. The conversion provisions of this note are the same as the 2012 Individual Convertible Notes as described above. The Company analyzed the note for derivative accounting consideration and determined that the conversion feature of the note qualifies for accounting treatment as a financial derivative. The conversion feature of this note was valued at $37,837 on the issuance date. As a result, the note was fully discounted and the fair value of the conversion feature in excess of the principal amount allocated to the note of $2,837 was expensed immediately as additional interest expense. For the nine months ended September 30, 2013, the Company recognized $2,632 of interest expense related to the amortization of the debt discount. At September 30, 2013, there was $32,368 of unamortized discount related to the note. In connection with the issuance of the note, warrants to purchase 140,000 shares of the Company’s common stock at $0.25 per share and 70,000 shares of the Company’s common stock at $0.50 per share were issued to the note holder. These warrants were valued at $2,588 using the Black-Scholes Model.

Note_9_Derivatives_Note_Conver

Note 9 - Derivatives - Note Conversion Feature (Note Conversion Feature [Member])	9 Months Ended
	Sep. 30, 2013
Note Conversion Feature [Member]	'
Note 9 - Derivatives - Note Conversion Feature [Line Items]	'
Derivatives and Fair Value [Text Block]	'
	Note 9 – Derivatives – Note Conversion Feature
	Due to the conversion feature contained in some of the notes the Company issued, the actual number of shares of common stock that would be required if a conversion of the notes was made through the issuance of the Company’s common stock cannot be predicted, and the Company could be required to issue an amount of shares that may cause it to exceed its authorized share amount. As a result, the conversion feature requires derivative accounting treatment and will be bifurcated from the note and “marked to market” each reporting period through the income statement. The fair value of the conversion feature of these notes was recognized as a derivative liability instrument and will be measured at fair value at each reporting period. In determining the fair value, the Company uses the Black-Scholes Model. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes Model.
	The following is a summary of the activity of the derivative liability for the nine months ended September 30, 2013:
	Fair value at December 31, 2012	$	364,802
	Decrease in value		(153,484	)
	Addition		255,890
	Reclassification from liability to equity as a result of note conversions		(57,222	)
	Fair value at September 30, 2013	$	409,986
	The derivative liability was valued using the Black-Scholes Model with the following assumptions:
		September 30,				December 31,
		2013				2012
	Risk free interest rate			0.10%			0.11%	to	0.16%
	Expected life (years)		0.3	to	0.9		0.01	to	2.1
	Dividend Yield			0%				0%
	Volatility		235%	to	259%		130%	to	219%

Note_10_Fair_Value_Measurement

Note 10 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Fair Value, Measurement Inputs, Disclosure [Text Block]	'
	Note 10 – Fair Value Measurements
	The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.  The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety.
	●	Level 1 – quoted prices in active markets for identical assets or liabilities.
	●	Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.
	●	Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.
	The following table summarizes fair value measurements by level at September 30, 2013, for assets and liabilities measured at fair value on a recurring basis:
			Level 1		Level 2		Level 3		Total
	Cash and cash equivalents		$	3,372	$	-	$	-	$	3,372
	Derivative liability			-		-		409,986		409,986
	The following table summarizes fair value measurements by level at December 31, 2012, for assets and liabilities measured at fair value on a recurring basis:
			Level 1		Level 2		Level 3		Total
	Cash and cash equivalents		$	54	$	-	$	-	$	54
	Derivative liability			-		-		364,802		364,802

Note_11_Commitments_And_Contin

Note 11 - Commitments And Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 11 – Commitment and Contingencies
	KVM Capital Partners Investment Agreement
	On June 11, 2013, the Company entered into an Investment Agreement (the “Investment Agreement”) with KVM Capital Partners (“KVM”), whereby the parties also agreed to enter into a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the terms of the Investment Agreement, for a period of 36 months commencing on the trading day immediately following date of effectiveness of the Registration Statement, KVM will commit to purchase up to $1,500,000 of the Company’s common stock, pursuant to a notice from the Company (“Puts”), covering the Registrable Securities (as defined below). The purchase price of the Shares under the Investment Agreement is equal to a 22.5% percent discount to the average of the three lowest closing bids during the last seven trading days after the Company delivers to KVM a Put notice in writing requiring KVM to purchase shares of the Company, subject to the terms of the Investment Agreement.
	The Registrable Securities include (1) shares of the Company’s common stock and (2) any shares of capital stock issued or issuable with respect to the Company’s common stock, if any, as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, which have not been (1) included in the Registration Statement that has been declared effective by the SEC, or (2) sold under circumstances meeting all of the applicable conditions of Rule 144 (or any similar provision then in force) under the 1933 Act.
	As further consideration for KVM entering into and structuring the Investment Agreement, the Company paid to KVM a $10,000 fee by issuing to KVM 250,000 restricted shares of its common stock on June 11, 2013.
	Maxxon/Globe Joint Venture Agreement
	In September 2005, the Company filed a patent on its RevVac™ Safety Syringe with Globe Med Tech which gave a 50% ownership of this patent to the Company and 50% to Globe Med Tech. On November 3, 2005, the Company (f.k.a. Maxxon, Inc.,) and Globe Med Tech, Inc. (“Globe”) entered into a definitive joint venture agreement (the “Joint Venture Agreement”) to patent, develop, manufacture, market and distribute safety needle products throughout the world.  The Company and Globe each owned 50% of the joint venture.   The Company contributed its safety syringe technology and patent rights related thereto and Globe contributed its safety syringe IV catheter and patent rights related thereto.  In connection with the Joint Venture Agreement, the Company issued restricted shares of its common stock, valued at $625,066, to Globe.  Subsequent to December 31, 2006, the Company ended the Joint Venture Agreement and cancelled the restricted shares of common stock that were issued to Globe pursuant to the agreement.  The above noted patent was issued on January 13, 2009.
	On March 1, 2007, the Company filed a lawsuit in the District Court of Tulsa County, Oklahoma against Globe to rescind, terminate and seek monetary damages for the non-fulfillment and breach of the Joint Venture Agreement, and other related agreements, in addition to an accounting of expenditures of funds under the terms and provisions of the agreements.  On October 29, 2008, the Company filed in the District Court of Harris County, Texas, a lawsuit for fraud and contempt of court for Globe and Andy Hu, individually.  On October 21, 2011, the Company was granted its request for summary judgment against Globe and awarded $311,440 and the return of 266,666 shares of the Company’s common stock by a Federal District Court in Tulsa County, Oklahoma.  In addition to the monetary award and the return of the Company’s common stock, Globe is also required to return all syringes, design files, and sample molds to the Company.  Furthermore, the Court ordered that Globe assign to the Company all rights to the patent issued on January 13, 2009 for the RevVac™ Safety Syringe.  Globe is prohibited from claiming any interest or ownership in the Company’s safety vacuum syringes going forward.
	On December 13, 2011, the Supreme Court of Oklahoma denied Globe’s appeal and, on January 30, 2013, the court ordered a Nunc Pro Tunc decision denying all counterclaims and third party claims by Globe.  On April 30, 2013, the Company exercised its legal rights under a writ of execution in Harris County, Texas, pursuant to which the Company, along with its attorneys and county constables, seized all valuable property from Globe Med Tech’s office including 266,666 restricted shares of common stock of Revolutions Medical, all design and patent files relating to its auto retractable vacuum safety syringe, furniture, computers, phones and other office equipment and information.  Globe’s web hosting company has been notified and ordered under the judgment and writ of execution to shut down Globe’s website until all information and references of ownership, patents and awards regarding the RevVac™ Safety Syringe are removed from the website. The Company will continue to use all available legal means under the judgment until all monies are collected and the judgment is satisfied in full. On August 27, 2013, the Company cancelled the 266,666 shares.
	MIG and SPD
	On January 2, 2013, the Company won its arbitration proceeding concerning its counter claims against Richard Theriault, former manufacturer MIG and former consultant, Strategic Product Development ("SPD").  The monetary award included $770,000 in recoupment of production costs plus interest, legal fees and other arbitration costs, which will total approximately $1 million. In other claims, Theriault was found guilty of fraud in the inducement and breach of contract and was found to have no rights to any of the Company's proprietary technology, files, drawings, designs, patents or products. A panel of the American Arbitration Association (“Arbitrator”) determined that all production mold payments made by the Company to MIG for the manufacturing of production molds had instead been used by Mr. Theriault for other non-production related purposes. The Arbitrator ruled that the only assets in which production was funded by MIG from the Company’s production payments were $10,000 in trial molds. The equipment asset on the balance sheet was reduced by $710,000 and charged to impairment of assets in 2012 as the payments were not associated with a production or trial mold. The $770,000 award is for the recovery of damages related to these production payments.  The gain related to this award will be recorded when collected. The Company has retained counsel in Massachusetts and South Carolina to assist in efforts to collect these damages.
	On September 26, 2012, the Company filed suit in South Carolina Federal District Court against SPD, Richard H. Theriault, Vita S. Theriault, Darius R. Theriault, Raminta Theriault, Goddard Technologies, Inc. ("GTI") and others, claiming that the defendants purposely and materially misled and misrepresented capabilities and progress on a variety of initiatives related to the development and manufacture of the Company's RevVac™ Safety Syringe to officers and directors of Revolutions Medical, which caused a delay in its production of approximately one year. The suit further alleges that Richard H. Theriault and other defendants defrauded the Company and misappropriated funds in violation of the United States' Racketeer Influenced and Corrupt Organizations Act and that GTI improperly assigned certain rights to the Company's new provisional patents to SPD without authorization. In February, 2013 the Company changed the venue to the United States District Court of Massachusetts against Goddard, and attended a case scheduling hearing on September 9, 2013.
	On February 2, 2013, Richard H. Theriault filed for bankruptcy in Massachusetts under Chapter 11.  The South Carolina lawsuit has been temporarily stayed until such time when the arbitration award against Richard H. Theriault and MIG can be ruled on in United States Federal District Court in Massachusetts, seeking judgment outside the bankruptcy court. On March 13, 2013, United States Federal District Court in Massachusetts granted an injunction against Richard H. Theriault and MIG, enjoining and restraining them from transferring or alienating any assets in their possession without approval from the Court. On May 6, 2013, that court upheld its ruling in favor of continuing the injunction. On September 17, 2013 the bankruptcy court has allowed the Company to lift the stay, confirm the judgment and proceed with its court cases and its efforts to seek monetary satisfaction of its award and other damages against Theriault, and his cohorts in South Carolina. Also, the Company is pursuing all of its rights in this bankruptcy to uncover additional assets in discovery that the Company has identified which were not disclosed or misappropriated in the Theriault bankruptcy filing.
	JMJ Financial, Inc.
	A lawsuit was filed against the Company by JMJ Financial (“JMJ”) in Miami-Dade County, Florida on March 15, 2012. The lawsuit claims that the Company breached the terms of the convertible debt agreement by failing to issue shares requested in a stock conversion by JMJ on January 9, 2012 for 1,000,000 shares and on January 30, 2012 for 1,226,049 shares.  JMJ is seeking the delivery of 2,226,049 shares of common stock of the Company, plus costs and prejudgment interest. On August 30, 2012, the Company filed its counterclaims against JMJ, which included fraud by concealment, among other claims. The Company alleges that Keener and JMJ had a responsibility and obligation under Florida law to disclose during the negotiations of the agreement the fact that Keener and JMJ had outstanding and current issues with these type of convertible notes with DTC which could do detrimental harm to liquidity and electronic transfer of the Company's stock if DTC eligibility was “chilled”. In the securities trading industry, the loss of eligibility for electronic trading, transfer, and delivery of common stock is known as a “chill”. This would severely hamper future capital raising and harm its current shareholders but would solely benefit Keener and JMJ under the default clauses in this agreement. On March 14, 2013 the Company did receive a letter from the DTC advising that a “chill” was placed on its stock. All of the JMJ share issuances were among the share issuances that the DTC identified to be reviewed. In July 2013, the Company won its motion to compel discovery from JMJ and Keener to provide all documents related to all financings with public companies that Keener and JMJ were involved, especially companies that DTC put a "chill" on their publicly traded stock and any regulatory actions or rulings against Keener and JMJ. On October 14, 2013, the DTC advised the Company that the “chill” had been lifted.
	SEC
	On September 20, 2012, the SEC filed a civil complaint in Federal District Court in Georgia against the Company, alleging that the Company issued four misleading press releases during the period from August 2010 through October 2010 and one misleading press release in July 2011, related to the Company’s production schedule of its RevVac™ safety syringe, pending government award and contract, and defense logistic agency product listings. The SEC names the Company’s current Chief Executive Officer, Rondald L. Wheet, as a co-defendant. Among other relief, the SEC seeks an order requiring the Company to disgorge approximately $1,100,000 received from its equity line financing from August 2010 through May 2011 with Auctus Private Equity Fund, in addition to other civil penalty amounts, and the SEC is seeking an officer and director bar against its Chief Executive Officer.
	In April 2013, through discovery and answers to interrogatories, the SEC identified Phillip Maurice Hicks a/k/a Marty Hicks as its tipster and invoked client attorney privilege on all correspondence with Hicks. In September 2011, a South Carolina Circuit Court declared Mr. Hicks to be liable by default for internet defamation of the Company and Rondald L. Wheet, CEO. On June 28, 2013, a special referee appointed by the South Carolina Court awarded the Company and Mr. Wheet more than $20 million in a default judgment against Mr. Hicks and ruled that Hicks intentionally interfered with its Department of Defense grant and contract with the HIV/AIDS prevention program. Specifically, the Company was awarded $3.6 million in compensatory damages and $1.5 million in punitive damages and Mr. Wheet was awarded $12 million in compensatory damages and $3 million in punitive damages. The deadline for appeal has passed for Hicks’ default judgment. Also, in April 2013, the SEC identified that the testimony under oath of Richard Theriault was instrumental in bringing the allegation against the Company and its CEO. In January 2013, the Arbitration Panel found Mr. Theriault committed fraud against the Company as part of its award. The Company and its legal team continue to vigorously defend the Company and its CEO against the allegation.
	TCA Global Credit Master Fund, L.P.
	On April 26, 2013 (the “Effective Date”), the Company finalized a securities purchase agreement with TCA. Pursuant to the terms of the purchase agreement, TCA shall purchase from the Company up to $2 million of senior secured convertible redeemable debentures.  The debentures shall be purchased in a series of closings and pursuant to the first such closing, as of the Effective Date, TCA purchased that certain senior convertible redeemable debenture in the amount of $250,000.  The Company’s obligations to TCA under the debentures are secured by that certain security agreement granting TCA an unconditional and continuing first priority security interest in all of the Company’s assets and that certain stock pledge agreement granting TCA a continuing and first priority security interest in certain stock of the Company.
	Under the purchase agreement, as consideration for advisory services provided by TCA to the Company prior to the Effective Date, the Company shall pay to TCA a fee by issuing to TCA that number of shares of the Company’s common stock that equal a dollar amount of $100,000 (the “Advisory Fee Shares”).  It is the intention of the Company and TCA that the value of the Advisory Fee Shares shall equal $100,000.  In the event the value of the Advisory Fee Shares issued to TCA does not equal $100,000 after the sale of all Advisory Fee Shares, the purchase agreement provides for an adjustment provision allowing for necessary action to adjust the number of shares issued.  Additionally, TCA shall receive certain other fees pursuant to the purchase agreement.

Note_12_Common_Stock_Transacti

Note 12 - Common Stock Transactions	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 12 – Common Stock Transactions
	During the nine months ended September 30, 2013, the Company issued 7,767,749 shares of common stock with a total value of $864,370 for consulting services, director fees, financing related fees and for wages and consulting fees accrued in 2012.
	Also, during the nine months ended September 30, 2013, the Company received $100,000 cash for the exercise of warrants and options for 1,150,000 shares of common stock.
	Also, during the nine months ended September 30, 2013, the Company issued 8,805,519 shares of common stock for the conversions of convertible notes and accrued interest totaling $311,883.
	In addition, during the nine months ended September 30, 2013, the Company issued 9,375,000 pledged shares in escrow to TCA as collateral for the securities purchase agreement entered on April 26, 2013.
	Further, the Company retired 266,666 shares of common stock on August 27, 2013 previously issued to Globe and issued 100,000 shares to an investor for proceeds of $12,500 received in 2012.

Note_13_Stock_Options_And_Warr

Note 13 - Stock Options And Warrants Outstanding	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 13 – Stock Options and Warrants Outstanding
	The Company’s 2007 Stock Option Plan, revised July 2011, permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 20 million shares of its common stock.  The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company.  The plan allows the Company to issue either stock options or common shares.
	From time to time, the Company enters into consulting agreements to perform marketing services for the Company as it begins to enter into the production stage for the RevVac™ Safety Syringe. Consultants are obligated under the contract to promote the product within various spheres of influence. These spheres of influence include, but are not limited to, medical product distributors, hospitals, doctors and government agencies.
	Consultants are issued options at a discount to the market price at the date of issuance. The amount to be determined for the consulting expense is determined based upon the options issued using the Black-Scholes Model.
	During the nine months ended September 30, 2013, under the terms of the Company’s 2007 Stock Option Plan, 1,975,000 options were issued for consulting services exercisable at $0.05~$0.50 per share. The options have a term of 10 days to one year and vest upon issuance. The aggregate fair value of these options equal to $51,642 was calculated using the Black-Scholes Model with the following assumptions: (1) discount rate of 0.10% to 0.18% (2) expected life of 0.03 to 1.06 years (3) expected volatility of 163% to 215% and (4) zero expected dividends.
	The following table summarizes the stock option activity:
		For the nine months ended September 30, 2013
		Number of Shares			Weighted-average
		Under Option			Exercise Price
	Outstanding at December 31, 2012		12,100,000		$	0.2
	Granted		1,975,000			0.17
	Exercised		(1,050,000	)		0.09
	Forfeited or expired		(925,000	)
	Outstanding at September 30, 2013		12,100,000			0.2
	The following table summarizes the warrant activity:
		For the nine months ended September 30, 2013
		Number of Shares			Weighted-average
		Under Option			Exercise Price
	Outstanding at December 31, 2012		2,013,003		$	0.5
	Granted		6,249,008			0.33
	Exercised		-
	Forfeited or expired		(2,013,003	)
	Outstanding at September 30, 2013		6,249,008			0.33

Note_14_Earnings_Loss_Per_Comm

Note 14 - Earnings (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 14 – Earnings (Loss) Per Common Share
	Basic net income (loss) per common share is calculated by dividing net income (loss) available to common stockholders for the period by the weighted average shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. The calculation of diluted net income (loss) per common share assumes the dilutive effect of stock options, warrants and any other potentially dilutive securities outstanding. During a loss period, the potentially dilutive securities have an anti-dilutive effect and are not included in the calculation of dilutive net income (loss) per common share. For the nine months ended September 30, 2013, potentially issuable shares, including options and warrants to purchase 18,349,008 shares of the Company’s common stock and notes payable convertible to 27,402,673 shares of the Company’s common stock, have been excluded from the calculation. For the nine months ended September 30, 2012, potentially issuable shares, including options and warrants to purchase 20,287,758 shares of the Company’s common stock and notes payable convertible to 10,122,496 shares of the Company’s common stock, have been excluded from the calculation.

Note_15_Related_Party_Transact

Note 15 - Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 15 – Related Party Transactions
	On September 1, 2009, the Company entered into a 5-year lease agreement with Osprey South, LLC (“Osprey”), to lease its corporate office space at 670 Marina Drive, Suite 301, Building F, Charleston, South Carolina, 29492.  Pursuant to the lease agreement, the Company was to pay Osprey $4,500 per month.  On July 1, 2011, the Company amended the lease agreement to include the office space adjacent to the existing office space.  Under the amended lease agreement, the lease term ends on July 1, 2016, and the Company is to pay Osprey $10,000 per month.  Rondald L. Wheet, our Chairman and Chief Executive Officer, is the sole member of Osprey.  For each of the nine months ended September 30, 2013 and 2012, the Company expensed $90,000 in lease payments to Osprey. Rent payable to Osprey was $82,962 and $19,761 as of September 30, 2013 and December 31, 2012, respectively. Future minimum lease payments due under the amended lease totaled approximately $330,000 at September 30, 2013.
	The following table sets forth amounts owed by the Company to its executive officers listed therein for expenses paid by said officers on behalf of the Company as of September 30, 2013 and December 31, 2012.
		September 30,		December 31,
		2013		2012
	Rondald L. Wheet, Chief Executive Officer	$	81,834	$	32,502
	Stephen Wheet, Director of Sales		8,620		-
	Vincent Olmo, Chief Operating Officer		3,057		9,194
		$	93,511	$	41,696
	The Company also had a convertible note payable to Mr. Olmo with principal amount of $75,000 at September 30, 2013 and $12,500 advance from shareholder at December 31, 2012.

Note_16_Restatement

Note 16 - Restatement	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Reclassifications [Text Block]	'
	NOTE 16 – Restatement
	The Company restated its statements of operations and cash flows for the three and nine months ended September 30, 2012 to reflect the following adjustments:
	• The increase in cost of goods sold of $313,437 for the loss on firm purchase commitment with Yeso-med.
	• The increase in payable for estimated penalties of $60,755 related payroll tax liabilities.
	• The increase in consulting fees of $34,860 for business development.
	• The increase in indemnification expense of $31,974 related to the revaluation of the shares held to indemnify the Company’s former CEO for the payment of penalties and interest agreed to in settlement of a case brought by the SEC against the Company and its former CEO.
	• The increase of stock compensation expense of $219,409 to properly value the shares issued for consulting services.
	• The decrease of $13,248 amortization expense to properly amortize the patent costs.
	• The increase of interest expense of $331,096 related to the amortization of beneficial conversion feature of certain convertible notes issued.
	The impact of the reclassifications and prior period adjustments on the accompanying statement of operations for the three and nine months ended September 30, 2012 is as follows:
	For the three months ended September 30, 2012:
		As			Change			As
		Originally						Restated
		Reported
	Cost of goods sold	$	219		$	313,437		$	313,656
	General and administrative expenses		826,489			126,460			952,949
	Depreciation and amortization		28,341			(4,416	)		23,925
	Interest expense		411,659			78,037			489,696
	Net loss attributable to common shareholders		1,311,664			512,540			1,824,204
	Income per common share - basic and diluted		(0.02	)					(0.03	)
	For the nine months ended September 30, 2012:
		As			Change			As
		Originally						Restated
		Reported
	Cost of goods sold	$	9,200		$	313,437		$	322,637
	General and administrative expenses		3,017,340			346,997			3,364,338
	Depreciation and amortization		67,136			(13,248	)		53,888
	Interest expense		1,198,603			331,096			1,529,699
	Net loss attributable to common shareholders		4,204,031			978,282			5,182,313
	Income per common share - basic and diluted		(0.07	)					(0.09	)
	The impact of the reclassifications and prior period adjustments on the accompanying statement of cash flows for the nine months ended September 30, 2012 is as follows:
		As			Change			As
		Originally						Restated
		Reported
	Net cash used in operating activities	$	(3,248,040	)	$	1,601,145		$	(1,646,895	)
	Net cash used in investing activities		(15,392	)		(14,929	)		(30,321	)
	Net cash provided by financing activities		3,259,661			(1,586,216	)		1,673,445

Note_17_Subsequent_Events

Note 17 - Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 17 – Subsequent Events
	On October 10, 2013, the Company issued 1,025,000 shares of common stock to settle a payable in the amount of $30,750.
	On October 15, 2013, the Company issued 3,518,072 shares of common stock to Asher for the conversion of a note payable.
	On October 21, 2013, the Company issued 1,429,454 shares to Carebourn Capital for the conversion of a note payable.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying unaudited financial statements include the accounts of Revolutions Medical Corporation, a Nevada corporation. Unless the context otherwise requires, references to the “Company”, “RevMed”, “our”, “we”, and “us” mean Revolutions Medical Corporation.
	The Company follows accounting standards set by the Financial Accounting Standards Board (“FASB”). The FASB establishes accounting principles generally accepted in the United States (“GAAP”). Rules and interpretive releases of the U.S. Securities and Exchange Commission (“SEC”) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants, which the Company is required to follow. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification (“ASC”), which serves as a single source of authoritative non-SEC accounting and reporting standards to be applied by nongovernmental entities.
	The Company’s financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation have been included.  The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Management has evaluated events and transactions that occurred after the balance sheet date and through the date these financial statements were issued and considered the effect of such events in the preparation of these financial statements.
	The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The financial statements contained herein should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
Nature of Operations [Text Block]	'
	Description of Business
	RevMed endeavors to design, develop and commercialize auto retractable vacuum safety syringes.  Our present product development effort is focused on the RevVac™ Auto Retractable Vacuum Safety Syringe (“RevVac™ Safety Syringe”), which is designed specifically to reduce accidental needle stick injuries and lower the spread of blood borne diseases.  The Company also has developed a suite of proprietary Magnetic Resonance Imaging (“MRI”) software tools consisting of RevColor™, Rev3D™, and RevDisplay™.  These tools are designed to enhance general diagnostic confidence through education and research use and in the future the Company believe will have specific commercial applications. The Company’s administrative facilities are located in Charleston, South Carolina and its primary manufacturing facility is located in Wuxi, China.
	Since its inception in 1996, the Company has been considered a development stage enterprise for financial reporting purposes as significant efforts have been devoted to raising capital for research and development of various safety syringes and its proprietary MRI software tools.
Significant Accounting Policies [Text Block]	'
	Significant Accounting Policies
	The Company has established and followed a number of accounting policies in the preparation of these financial statements in conformity with GAAP.  Significant among these policies are policies related to cash and cash equivalents, inventories, property and equipment, intangibles, impairment of long-lived assets, research and development, convertible debt with beneficial conversion features, derivative instruments, fair value of financial instruments, revenue recognition and stock-based compensation.  These accounting policies are more fully described in the notes to the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2012.
Use of Estimates, Policy [Policy Text Block]	'
	Critical Accounting Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ significantly from those estimates.
Reclassification, Policy [Policy Text Block]	'
	Reclassification
	Certain prior period amounts have been reclassified to conform to current period presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	New and Pending Accounting Standards
	The Company does not anticipate that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company. In addition, the Company is evaluating other accounting standards and exposure drafts, such as exposure drafts related to revenue recognition, leases and fair value measurements, that have been issued or proposed by the FASB or other standard setting bodies that do not require adoption until a future date to determine whether adoption will have a material impact on the Company’s financial statements.

Note_3_Property_And_Equipment_

Note 3 - Property And Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		September 30,			December 31,
		2013			2012
	Equipment	$	353,235		$	353,235
	Leasehold improvement		44,000			44,000
	Furniture		49,147			49,147
			446,382			446,382
	Less accumulated depreciation		(154,577	)		(89,726	)
		$	291,805		$	356,656

Note_4_Intangibles_Tables

Note 4 - Intangibles (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		September 30,			December 31,
		2013			2012
	Patent	$	168,348		$	146,538
	Less accumulated amortization		(47,727	)		(39,851	)
		$	120,621		$	106,687

Note_5_Accounts_Payable_And_Ac1

Note 5 - Accounts Payable And Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		September 30,		December 31,
		2013		2012
	Accounts payable	$	491,959	$	432,436
	Accrued payroll liabilities and related penalties		598,815		411,670
	Accrued salary		295,273		143,167
	Accrued interest		147,543		134,559
	Other accruals		539		539
		$	1,534,129	$	1,122,371

Note_8_Convertible_Notes_Table

Note 8 - Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Short-term Debt [Table Text Block]	'
		September 30,			December 31,
		2013			2012
	Convertible Promissory Note Payable to JMJ Financial, unsecured, one time interest charge of 8%, due on February 22, 2014	$	191,663		$	191,663
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on March 21, 2013, fully converted in 2013		-			7,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 10, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on August 27, 2013, fully converted in 2013		-			42,500
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on December 6, 2013		27,500			-
	Convertible Promissory Note Payable to Asher Enterprises, unsecured, interest rate of 8% per annum, with payment due on May 19, 2014		35,000			-
	Convertible Promissory Note Payable to Carebourn Capital L.P., unsecured, interest rate of 8% per annum, with payment due on December 19, 2013		23,411			-
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due on January 3, 2013		-			62,165
	Convertible Promissory Note Payable to TCA Global Credit Master Fund, LP, secured by all of the Company's assets, interest rate of 12% per annum, with payment due monthly until April 26, 2014		215,970			-
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on September 3, 2014		35,000			-
	Convertible Promissory Note Payable issued in the course of a private placement to individual, unsecured, interest rate of 8% per annum, with payment due on January 26, 2014		75,000			100,000
			603,544			446,328
	Less: debt discount		(216,394	)		(229,573	)
		$	387,150		$	216,755

Note_9_Derivatives_Note_Conver1

Note 9 - Derivatives - Note Conversion Feature (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Schedule of Derivative Instruments [Table Text Block]	'
	Fair value at December 31, 2012	$	364,802
	Decrease in value		(153,484	)
	Addition		255,890
	Reclassification from liability to equity as a result of note conversions		(57,222	)
	Fair value at September 30, 2013	$	409,986
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	'
		September 30,				December 31,
		2013				2012
	Risk free interest rate			0.10%			0.11%	to	0.16%
	Expected life (years)		0.3	to	0.9		0.01	to	2.1
	Dividend Yield			0%				0%
	Volatility		235%	to	259%		130%	to	219%

Note_10_Fair_Value_Measurement1

Note 10 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
		Level 1		Level 2		Level 3		Total
	Cash and cash equivalents	$	3,372	$	-	$	-	$	3,372
	Derivative liability		-		-		409,986		409,986
		Level 1		Level 2		Level 3		Total
	Cash and cash equivalents	$	54	$	-	$	-	$	54
	Derivative liability		-		-		364,802		364,802

Note_13_Stock_Options_And_Warr1

Note 13 - Stock Options And Warrants Outstanding (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
		For the nine months ended September 30, 2013
		Number of Shares			Weighted-average
		Under Option			Exercise Price
	Outstanding at December 31, 2012		12,100,000		$	0.2
	Granted		1,975,000			0.17
	Exercised		(1,050,000	)		0.09
	Forfeited or expired		(925,000	)
	Outstanding at September 30, 2013		12,100,000			0.2
		For the nine months ended September 30, 2013
		Number of Shares			Weighted-average
		Under Option			Exercise Price
	Outstanding at December 31, 2012		2,013,003		$	0.5
	Granted		6,249,008			0.33
	Exercised		-
	Forfeited or expired		(2,013,003	)
	Outstanding at September 30, 2013		6,249,008			0.33

Note_15_Related_Party_Transact1

Note 15 - Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
		September 30,		December 31,
		2013		2012
	Rondald L. Wheet, Chief Executive Officer	$	81,834	$	32,502
	Stephen Wheet, Director of Sales		8,620		-
	Vincent Olmo, Chief Operating Officer		3,057		9,194
		$	93,511	$	41,696

Note_16_Restatement_Tables

Note 16 - Restatement (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	'
		As			Change			As
		Originally						Restated
		Reported
	Cost of goods sold	$	219		$	313,437		$	313,656
	General and administrative expenses		826,489			126,460			952,949
	Depreciation and amortization		28,341			(4,416	)		23,925
	Interest expense		411,659			78,037			489,696
	Net loss attributable to common shareholders		1,311,664			512,540			1,824,204
	Income per common share - basic and diluted		(0.02	)					(0.03	)
		As			Change			As
		Originally						Restated
		Reported
	Cost of goods sold	$	9,200		$	313,437		$	322,637
	General and administrative expenses		3,017,340			346,997			3,364,338
	Depreciation and amortization		67,136			(13,248	)		53,888
	Interest expense		1,198,603			331,096			1,529,699
	Net loss attributable to common shareholders		4,204,031			978,282			5,182,313
	Income per common share - basic and diluted		(0.07	)					(0.09	)
		As			Change			As
		Originally						Restated
		Reported
	Net cash used in operating activities	$	(3,248,040	)	$	1,601,145		$	(1,646,895	)
	Net cash used in investing activities		(15,392	)		(14,929	)		(30,321	)
	Net cash provided by financing activities		3,259,661			(1,586,216	)		1,673,445

Note_2_Going_Concern_Details

Note 2 - Going Concern (Details) (USD $)	3 Months Ended		9 Months Ended		205 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Going Concern Note [Abstract]	'	'	'	'	'
Net Income (Loss) Attributable to Parent	($925,666)	($1,824,205)	($4,048,052)	($5,182,314)	($41,986,773)

Note_3_Property_And_Equipment_1

Note 3 - Property And Equipment (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation	$64,851	$47,391

Note_3_Property_And_Equipment_2

Note 3 - Property And Equipment (Details) - Summary of Property and Equipment (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$446,382	$446,382
Less accumulated depreciation	-154,577	-89,726
	291,805	356,656
Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	353,235	353,235
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	44,000	44,000
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$49,147	$49,147

Note_4_Intangibles_Details

Note 4 - Intangibles (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Amortization of Intangible Assets	$7,876	$6,497

Note_4_Intangibles_Details_Sum

Note 4 - Intangibles (Details) - Summary of Intangible Assets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Less accumulated amortization	($47,727)	($39,851)
	120,621	106,687
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Patent	$168,348	$146,538

Note_5_Accounts_Payable_And_Ac2

Note 5 - Accounts Payable And Accrued Liabilities (Details) (USD $)

3 Months Ended

9 Months Ended

205 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Jun. 18, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Related to Minimum Purchase Requirement [Member]

Related to Minimum Purchase Requirement [Member]

Product Purchase [Member]

Product Purchase [Member]

Equipment Purchase [Member]

Equipment Purchase [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Yeso Med [Member]

Note 5 - Accounts Payable And Accrued Liabilities (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Payroll Taxes, Current

$598,815

'

$598,815

'

$598,815

$411,670

'

'

'

'

'

'

'

'

'

'

'

Tax Lien, Amount

'

'

'

'

'

'

6,457

'

'

'

'

'

'

'

'

'

'

Long-term Purchase Commitment, Time Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'5

'

'

'

Long-term Purchase Commitment, Minimum Quantity Required

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

Purchase Commitment, Percentage of Supply Price

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

Accounts Payable, Current

'

'

'

'

'

'

'

2,252,950

783,593

208,501

208,258

289,519

289,009

'

2,750,970

'

1,280,860

Loss on Purchase Commitments

$493,328

$313,437

$1,469,357

$313,437

$2,252,950

'

'

'

'

'

'

'

'

'

$1,500,000

$313,437

'

Note_5_Accounts_Payable_And_Ac3

Note 5 - Accounts Payable And Accrued Liabilities (Details) - Summary of Accounts Payable and Accrued Liabilities (USD $)	Sep. 30, 2013	Dec. 31, 2012
Summary of Accounts Payable and Accrued Liabilities [Abstract]	'	'
Accounts payable	$491,959	$432,436
Accrued payroll liabilities and related penalties	598,815	411,670
Accrued salary	295,273	143,167
Accrued interest	147,543	134,559
Other accruals	539	539
	$1,534,129	$1,122,371

Note_7_Payable_for_Indemnifica1

Note 7 - Payable for Indemnification (Details) (USD $)	0 Months Ended		9 Months Ended
	Mar. 15, 2012	Dec. 14, 2010	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Feb. 05, 2009
Disclosure Text Block [Abstract]	'	'	'	'	'	'
	'	'	$1,372,466	'	$1,347,806	$1,088,067
Stock Issued During Period, Shares, for Indemnification (in Shares)	400,000	400,000	'	'	'	'
Stock Issued During Period, Value, for Indemnification	140,560	184,000	'	'	'	'
Net Loss on Stock Held in Special Account for Indemnification	'	'	$24,659	$31,974	'	'
Common Stock Held in Special Account for Indemnification, Shares (in Shares)	'	'	301,463	'	'	'

Note_8_Convertible_Notes_Detai

Note 8 - Convertible Notes (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

205 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

8 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Apr. 26, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Apr. 25, 2013

Dec. 31, 2012

Sep. 30, 2013

Apr. 25, 2013

Dec. 31, 2012

Apr. 25, 2013

Mar. 02, 2013

Aug. 28, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Apr. 26, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Jan. 03, 2012

Dec. 31, 2012

Feb. 22, 2011

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 12, 2013

Aug. 15, 2013

Feb. 28, 2013

Sep. 30, 2013

Sep. 20, 2013

Mar. 19, 2013

Sep. 30, 2013

9-May-13

Jan. 03, 2013

Jan. 03, 2012

9-May-13

Apr. 26, 2013

Sep. 30, 2013

Dec. 31, 2012

Apr. 25, 2013

Sep. 03, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Stock Issued as Collateral [Member]

Stock Issued as Collateral [Member]

Related to Conversion Feature [Member]

$0.25 Warrant [Member]

$0.25 Warrant [Member]

$0.25 Warrant [Member]

$0.50 Warrant [Member]

$0.50 Warrant [Member]

$0.50 Warrant [Member]

Warrants, Related to Individual Convertible Notes [Member]

Warrants, Related to Individual Convertible Notes [Member]

Warrants, Related to Individual Convertible Notes [Member]

Warrants, Related to Individual Convertible Notes [Member]

Warrants, Related to Individual Convertible Notes [Member]

Warrants, Related to Individual Convertible Notes [Member]

2013 TCA Purchase Agreement [Member]

2013 TCA Purchase Agreement [Member]

Chief Operating Officer [Member]

Chief Operating Officer [Member]

Chief Operating Officer [Member]

Chief Operating Officer [Member]

TCA Global Credit Master Fund, LP [Member]

TCA Global Credit Master Fund, LP [Member]

JMJ Note [Member]

JMJ Note [Member]

JMJ Note [Member]

JMJ Note [Member]

Asher Note 2013 [Member]

Asher Note 2013 [Member]

Asher Note 2013 [Member]

Asher Note 2013 [Member]

Carebourn Note 2013 [Member]

Carebourn Note 2013 [Member]

Carebourn Note 2013 [Member]

TCA Note [Member]

TCA Note [Member]

TCA Note [Member]

TCA Debentures [Member]

TCA Debentures [Member]

Individual Convertible Notes [Member]

Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

TCA Debentures [Member]

Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

Minimum [Member]

Maximum [Member]

Individual Convertible Notes [Member]

Individual Convertible Notes [Member]

2013 Individual Convertible Notes [Member]

Note 8 - Convertible Notes (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$250,000

'

$75,000

'

$75,000

$75,000

'

'

$1,050,000

$191,663

'

'

'

'

'

'

'

'

'

'

'

$225,000

'

$250,000

'

'

$50,000

$35,000

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

8.00%

'

8.00%

'

'

'

'

'

'

'

Percentage Of Common Stock Closing Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.02

'

'

'

'

'

$0.00

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,498

15,000

'

'

97,600

36,590

'

'

'

27,840

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

8,805,519

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

180,000

1,339,286

'

'

2,726,118

2,350,000

'

'

1,750,000

300,000

'

'

'

353,727

'

1,000,000

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,500

111,893

0

42,534

'

'

'

'

450,000

30,721

'

106,691

'

'

'

35,839

'

'

5,572

'

'

'

'

'

0

55,952

'

'

32,368

'

'

'

'

'

'

Interest Expense, Debt (in Dollars)

'

2,838

146,445

'

399,312

'

'

182,733

'

'

'

'

'

'

'

'

'

'

'

'

'

9,761

'

'

'

'

'

'

'

75,970

60,000

'

'

'

'

66,930

'

'

'

'

'

'

'

'

55,952

'

'

2,837

2,632

'

'

'

'

'

'

Proceeds from Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,000

42,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

130,117

436,184

'

488,879

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

218,053

'

'

'

'

'

'

'

'

'

'

'

'

'

77,500

'

'

49,091

'

'

'

174,448

'

'

'

777,766

'

37,837

'

'

'

'

'

'

'

Amortization of Debt Discount (Premium)

'

413,851

1,071,734

'

2,275,069

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,661

'

'

43,519

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Convertible Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Purchase Agreement, Amount to be Purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Facility Fee Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

100,000

'

9,375,000

9,375,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

559,268

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Facility Fee Satisfied

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,924

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

140,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Original Debt, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

106,987

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gains (Losses) on Extinguishment of Debt

-4,082

-43,345

'

'

-183,057

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33,013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Leak Out Provision Threshold Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,000

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Inputs, Discount Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.10%

'

'

0.18%

'

Debt Instrument Late Fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

51,530

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Convertible Price Percentage of Weighted Average Price of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues (in Dollars)

'

'

'

'

'

9,375

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Debt

'

472,500

1,368,001

'

3,448,501

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

956,501

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

140,000

200,000

3,826,005

70,000

100,000

1,913,003

'

2,859,008

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

'

0.25

0.25

0.25

0.5

0.5

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Debt Allocated to Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

347,097

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$589,416

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

0.10%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.11%

'

'

0.16%

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

155.60%

218.64%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

235.00%

'

130.00%

259.00%

'

219.00%

Fair Value Assumptions, Expected Dividend Payments (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'109 days

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'109 days

'

'3 days

'328 days

'

'2 years 36 days

Modification Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

148,127

40,501

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,526

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,588

'

'

'

'

'

'

Note_8_Convertible_Notes_Detai1

Note 8 - Convertible Notes (Details) - Notes Payable (USD $)	Sep. 30, 2013	Dec. 31, 2012
Short-term Debt [Line Items]	'	'
	$312,150	$184,289
Including Related Parties [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	603,544	446,328
Less: debt discount	-216,394	-229,573
	387,150	216,755
Private Placement [Member] | Due September 3, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	35,000	'
Private Placement [Member] | Due January 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	75,000	100,000
JMJ Financial Inc [Member] | Due February 22, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	191,663	191,663
Asher Enterprises Inc [Member] | Due March 21, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	7,500
Asher Enterprises Inc [Member] | Due May 10, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	42,500
Asher Enterprises Inc [Member] | Due August 27, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	42,500
Asher Enterprises Inc [Member] | Due December 6, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	27,500	'
Asher Enterprises Inc [Member] | Due May 19, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	35,000	'
Carebourn Capital L.P. [Member] | Due December 19, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	23,411	'
TCA Global Credit Master Fund, LP [Member] | Due January 3, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	'	62,165
TCA Global Credit Master Fund, LP [Member] | Due April 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
Convertible Promissory Note Payable	$215,970	'

Note_8_Convertible_Notes_Detai2

Note 8 - Convertible Notes (Details) - Notes Payable (Parentheticals)	Sep. 30, 2013	Dec. 31, 2012
Private Placement [Member] | Due September 3, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Private Placement [Member] | Due January 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
JMJ Financial Inc [Member] | Due February 22, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	8.00%
Asher Enterprises Inc [Member] | Due March 21, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	'	8.00%
Asher Enterprises Inc [Member] | Due May 10, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	'	8.00%
Asher Enterprises Inc [Member] | Due August 27, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	'	8.00%
Asher Enterprises Inc [Member] | Due December 6, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Asher Enterprises Inc [Member] | Due May 19, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
Carebourn Capital L.P. [Member] | Due December 19, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	8.00%	'
TCA Global Credit Master Fund, LP [Member] | Due January 3, 2013 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	'	12.00%
TCA Global Credit Master Fund, LP [Member] | Due April 26, 2014 [Member]	'	'
Short-term Debt [Line Items]	'	'
ConvP5rtiblP5 Promissory NotP5 PayablP5, IntP5rP5st ratP5	12.00%	'

Note_9_Derivatives_Note_Conver2

Note 9 - Derivatives - Note Conversion Feature (Details) - Reconciliation of Derivative Liability (USD $)	9 Months Ended
	Sep. 30, 2013
Reconciliation of Derivative Liability [Abstract]	'
Fair value	$364,802
Decrease in value	-153,484
Addition	255,890
Reclassification from liability to equity as a result of note conversions	-57,222
Fair value	$409,986

Note_9_Derivatives_Note_Conver3

Note 9 - Derivatives - Note Conversion Feature (Details) - Fair Value Assumptions, Derivative Liability	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	0.10%	'
Dividend Yield	0.00%	0.00%
Minimum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	'	0.11%
Expected life (years)	'109 days	'3 days
Volatility	235.00%	130.00%
Maximum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Risk free interest rate	'	0.16%
Expected life (years)	'328 days	'2 years 36 days
Volatility	259.00%	219.00%

Note_10_Fair_Value_Measurement2

Note 10 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
Note 10 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]	'	'
Cash and cash equivalents	$3,372	$54
Derivative liability	409,986	364,802
Fair Value, Inputs, Level 1 [Member]	'	'
Note 10 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]	'	'
Cash and cash equivalents	3,372	54
Derivative liability	'	0
Fair Value, Inputs, Level 2 [Member]	'	'
Note 10 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]	'	'
Cash and cash equivalents	'	0
Derivative liability	'	0
Fair Value, Inputs, Level 3 [Member]	'	'
Note 10 - Fair Value Measurements (Details) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]	'	'
Cash and cash equivalents	'	0
Derivative liability	$409,986	$364,802

Note_11_Commitments_And_Contin1

Note 11 - Commitments And Contingencies (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

205 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Jan. 02, 2013

Sep. 20, 2012

Oct. 21, 2011

Dec. 31, 2012

Sep. 30, 2013

Aug. 27, 2013

Jun. 11, 2013

Jun. 11, 2013

Sep. 30, 2005

Oct. 21, 2011

Apr. 26, 2013

Dec. 31, 2012

Jan. 02, 2013

Mar. 15, 2012

Jun. 11, 2013

Apr. 26, 2013

Jun. 28, 2013

Jun. 28, 2013

Jun. 28, 2013

Jun. 28, 2013

Jun. 28, 2013

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Advisory Fee Requirement [Member]

Mold Production Payments [Member]

Mold Production Payments [Member]

JMJ Financial Inc [Member]

As Further Consideration for KVM Entering Into Investment Agreement [Member]

TCA Debentures [Member]

Default Judgement [Member]

Compensatory Damages [Member]

Punitive Damages [Member]

Mr. Wheet - Compensatory Damages [Member]

Mr. Wheet - Punitive Damages [Member]

Note 11 - Commitments And Contingencies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Obligation

'

'

'

'

'

'

$1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Price of Stock, Percent

'

'

'

'

'

'

22.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for Fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

100,000

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues (in Dollars)

'

'

'

'

'

'

'

'

625,066

'

'

'

'

'

'

'

'

'

'

'

'

Litigation Settlement, Amount

'

'

311,440

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

3,600,000

1,500,000

12,000,000

3,000,000

Litigation Settlement, Shares (in Shares)

'

'

'

'

'

'

'

'

'

266,666

'

'

'

'

'

'

'

'

'

'

'

Shares Cancelled (in Shares)

'

'

'

'

'

266,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain Contingency, Unrecorded Amount

770,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Legal Settlements

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Gross

'

'

'

446,382

446,382

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

Asset Impairment Charges

'

'

'

'

4,570,007

'

'

'

'

'

'

710,000

'

'

'

'

'

'

'

'

'

Requested Shares Of Common Stock Conversion (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

2,226,049

'

'

'

'

'

'

'

Loss Contingency, Damages Sought, Value

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Securities Purchase Agreement, Amount to be Purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

Convertible Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

Other Commitment

'

'

'

'

'

'

'

'

'

'

$100,000

'

'

'

'

'

'

'

'

'

'

Note_12_Common_Stock_Transacti1

Note 12 - Common Stock Transactions (Details) (USD $)	1 Months Ended	9 Months Ended		12 Months Ended	205 Months Ended
	Aug. 27, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013
Note 12 - Common Stock Transactions (Details) [Line Items]	'	'	'	'	'
Stock Issued During Period, Shares, Issued for Services	'	7,767,749	'	'	'
Stock Issued During Period, Value, Issued for Services (in Dollars)	'	$864,370	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	100,000	'
Debt Conversion, Converted Instrument, Shares Issued	'	8,805,519	'	'	'
Interest Expense, Debt (in Dollars)	'	2,838	146,445	'	399,312
Treasury Stock, Shares, Retired	266,666	'	'	'	'
Proceeds from Issuance of Common Stock (in Dollars)	'	'	'	12,500	8,163,410
Warrants and Options Exercised [Member]	'	'	'	'	'
Note 12 - Common Stock Transactions (Details) [Line Items]	'	'	'	'	'
Proceeds from Warrant Exercises (in Dollars)	'	100,000	'	'	'
Stock Issued During Period, Shares, New Issues	'	1,150,000	'	'	'
Converted into Shares [Member]	'	'	'	'	'
Note 12 - Common Stock Transactions (Details) [Line Items]	'	'	'	'	'
Interest Expense, Debt (in Dollars)	'	$311,883	'	'	'
Stock Issued as Collateral [Member]	'	'	'	'	'
Note 12 - Common Stock Transactions (Details) [Line Items]	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	9,375,000	'	'	'

Note_13_Stock_Options_And_Warr2

Note 13 - Stock Options And Warrants Outstanding (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Jul. 31, 2011
Note 13 - Stock Options And Warrants Outstanding (Details) [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	'	'	20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	1,975,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)	$51,642	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	'	163.00%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars)	'	$0	'
For Consulting Services, Exercisable at $0.10 [Member]	'	'	'
Note 13 - Stock Options And Warrants Outstanding (Details) [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)	1,975,000	'	'
For Consulting Services, Exercisable at $.05 [Member]	'	'	'
Note 13 - Stock Options And Warrants Outstanding (Details) [Line Items]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)	$0.05	'	'
For Consulting Services, Exercisable at $0.50 [Member]	'	'	'
Note 13 - Stock Options And Warrants Outstanding (Details) [Line Items]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)	$0.50	'	'
Minimum [Member]	'	'	'
Note 13 - Stock Options And Warrants Outstanding (Details) [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'10 days	'	'
Fair Value Inputs, Discount Rate	'	0.10%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'	'10 days	'
Maximum [Member]	'	'	'
Note 13 - Stock Options And Warrants Outstanding (Details) [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'1 year	'	'
Fair Value Inputs, Discount Rate	'	0.18%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'	'1 year 21 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	'	215.00%	'

Note_13_Stock_Options_And_Warr3

Note 13 - Stock Options And Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities (USD $)	9 Months Ended
	Sep. 30, 2013
Note 13 - Stock Options And Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities [Line Items]	'
Stock Option, Number of Units	12,100,000
Stock Option, Weighted Average Exercise Price (in Dollars per share)	$0.20
Granted	1,975,000
Granted (in Dollars per share)	$0.17
Exercised	-1,050,000
Exercised (in Dollars per share)	$0.09
Forfeited or expired	-925,000
Stock Option, Number of Units	12,100,000
Stock Option, Weighted Average Exercise Price (in Dollars per share)	$0.20
Warrant [Member]	'
Note 13 - Stock Options And Warrants Outstanding (Details) - Stock Options and Warrants Outstanding Activities [Line Items]	'
Warrant, Number of Units	2,013,003
Warrant, Weighted Average Exercise Price (in Dollars per share)	$0.50
Granted	6,249,008
Granted (in Dollars per share)	$0.33
Forfeited or expired	-2,013,003
Warrant, Number of Units	6,249,008
Warrant, Weighted Average Exercise Price (in Dollars per share)	$0.33

Note_14_Earnings_Loss_Per_Comm1

Note 14 - Earnings (Loss) Per Common Share (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Stock Options and Warrants [Member]	'	'
Note 14 - Earnings (Loss) Per Common Share (Details) [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	18,349,008	20,287,758
Convertible Debt Securities [Member]	'	'
Note 14 - Earnings (Loss) Per Common Share (Details) [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	27,402,673	10,122,496

Note_15_Related_Party_Transact2

Note 15 - Related Party Transactions (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Jul. 01, 2011	Sep. 01, 2009
Osprey South, LLC [Member]	'	'	'	'	'
Note 15 - Related Party Transactions (Details) [Line Items]	'	'	'	'	'
Operating Leases, Monthly Payments	'	'	'	$10,000	$4,500
Operating Leases, Rent Expense	90,000	90,000	'	'	'
Accrued Rent	82,962	'	19,761	'	'
Operating Leases, Future Minimum Payments Due	330,000	'	'	'	'
Chief Operating Officer [Member]	'	'	'	'	'
Note 15 - Related Party Transactions (Details) [Line Items]	'	'	'	'	'
Convertible Notes Payable	75,000	'	'	'	'
Shareholder [Member]	'	'	'	'	'
Note 15 - Related Party Transactions (Details) [Line Items]	'	'	'	'	'
Related Party Transaction, Due from (to) Related Party	'	'	($12,500)	'	'

Note_15_Related_Party_Transact3

Note 15 - Related Party Transactions (Details) - Amounts Owed by the Company to its Executive Officers (USD $)	Sep. 30, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]	'	'
Due to Related Parties	$93,511	$41,696
Chief Executive Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Due to Related Parties	81,834	32,502
Director of Sales [Member]	'	'
Related Party Transaction [Line Items]	'	'
Due to Related Parties	8,620	'
Chief Operating Officer [Member]	'	'
Related Party Transaction [Line Items]	'	'
Due to Related Parties	$3,057	$9,194

Note_16_Restatement_Details

Note 16 - Restatement (Details) (USD $)	9 Months Ended
	Sep. 30, 2012
Increase in Option Expense due to Changes in Valuation Technique [Member]	'
Note 16 - Restatement (Details) [Line Items]	'
Prior Period Reclassification Adjustment	$313,437
Increase in Payable for Estimated Penalties Related Payroll Tax Liabilities [Member]	'
Note 16 - Restatement (Details) [Line Items]	'
Prior Period Reclassification Adjustment	60,755
Increase in Consulting Fees for Business Development [Member]	'
Note 16 - Restatement (Details) [Line Items]	'
Prior Period Reclassification Adjustment	34,860
Increase in Indemnification Expense [Member]	'
Note 16 - Restatement (Details) [Line Items]	'
Prior Period Reclassification Adjustment	31,974
Increase of Stock Compensation Expense [Member]	'
Note 16 - Restatement (Details) [Line Items]	'
Prior Period Reclassification Adjustment	219,409
Decrease in Patent Amortization Expense [Member]	'
Note 16 - Restatement (Details) [Line Items]	'
Prior Period Reclassification Adjustment	13,248
Increase in Interest Expense [Member]	'
Note 16 - Restatement (Details) [Line Items]	'
Prior Period Reclassification Adjustment	$331,096

Note_16_Restatement_Details_Re

Note 16 - Restatement (Details) - Reclassifications and Prior Period Adjustments (USD $)	3 Months Ended		9 Months Ended		205 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cost of goods sold	$494,666	$313,656	$1,471,997	$322,637	$2,264,790
General and administrative expenses	480,460	952,949	2,144,070	3,364,338	29,442,874
Depreciation and amortization	24,789	23,925	72,727	53,888	277,838
Interest expense	207,414	489,696	474,098	1,529,699	3,103,803
Net loss attributable to common shareholders	'	1,824,204	'	5,182,313	'
Income per common share - basic and diluted (in Dollars per share)	($0.01)	($0.03)	($0.05)	($0.09)	'
Net cash used in operating activities	'	'	-495,842	-1,646,895	-14,284,494
Net cash used in investing activities	'	'	-21,810	-30,321	-1,437,458
Net cash provided by financing activities	'	'	520,970	1,673,445	15,725,324
Scenario, Previously Reported [Member]	'	'	'	'	'
Cost of goods sold	'	219	'	9,200	'
General and administrative expenses	'	826,489	'	3,017,340	'
Depreciation and amortization	'	28,341	'	67,136	'
Interest expense	'	411,659	'	1,198,603	'
Net loss attributable to common shareholders	'	1,311,664	'	4,204,031	'
Income per common share - basic and diluted (in Dollars per share)	'	($0.02)	'	($0.07)	'
Net cash used in operating activities	'	'	'	-3,248,040	'
Net cash used in investing activities	'	'	'	-15,392	'
Net cash provided by financing activities	'	'	'	3,259,661	'
Restatement Adjustment [Member]	'	'	'	'	'
Cost of goods sold	'	313,437	'	313,437	'
General and administrative expenses	'	126,460	'	346,997	'
Depreciation and amortization	'	-4,416	'	-13,248	'
Interest expense	'	78,037	'	331,096	'
Net loss attributable to common shareholders	'	512,540	'	978,282	'
Net cash used in operating activities	'	'	'	1,601,145	'
Net cash used in investing activities	'	'	'	-14,929	'
Net cash provided by financing activities	'	'	'	($1,586,216)	'

Note_17_Subsequent_Events_Deta

Note 17 - Subsequent Events (Details) (USD $)	9 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Oct. 15, 2013	Oct. 21, 2013	Oct. 10, 2013
			Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
			Asher Enterprises Inc [Member]	Carebourn Capital L.P. [Member]
Note 17 - Subsequent Events (Details) [Line Items]	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	100,000	3,518,072	'	1,025,000
Stock Issued During Period, Value, New Issues (in Dollars)	'	'	'	'	$30,750
Debt Conversion, Converted Instrument, Shares Issued	8,805,519	'	'	1,429,454	'